Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yongzhen Zhou, Chenjie Qiu, Qingsheng Fu, Tao Li, Xudong Zhang, Chunfu Zhu, Xihu Qin & Baoqiang Wu. (2023) Pan-Cancer Analysis of Oncogenic Role of RAD54L and Experimental Validation in Hepatocellular Carcinoma. Journal of Inflammation Research 16, pages 3997-4017.
Read now
Read now
Emily Hays, Elizabeth Nettleton, Caitlin Carter, Mariangel Morales, Lynn Vo, Max Passo & Renier Vélez-Cruz. (2020) The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease. Cell Cycle 19:22, pages 3096-3114.
Read now
Read now
Articles from other publishers (24)
E. M. Kagirova, R. I. Khusainova & I. R. Minniakhmetov. (2023) Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements. Siberian journal of oncology 22:5, pages 118-133.
Crossref
Crossref
Laura Guantay, Cintia Garro, Sebastián Siri, María Florencia Pansa, Sonja Ghidelli-Disse, Natalia Paviolo, Ana Racca, Viviana Nicotra, Caius Radu, José Luis Bocco, Rosana Felice, Keith H. Jansson, Katja Remlinger, Alejandro Amador, Euan Stronach, Kevin Coleman, Marcel Muelbaier, Gerard Drewes, Isro Gloger, Kevin Madauss, Manuela García, Vanesa Gottifredi & Gastón Soria. (2023) Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency. Drug Resistance Updates 67, pages 100932.
Crossref
Crossref
Abraham B. Korol & Sviatoslav R. Rybnikov. 2023. Reference Module in Life Sciences. Reference Module in Life Sciences.
Pan Li, Chaohu Chen, Jianpeng Li, Li Yang, Yuhan Wang, Zhilong Dong, Jun Mi, Yunxin Zhang, Juan Wang, Hanzhang Wang, Ronald Rodriguez, Junqiang Tian & Zhiping Wang. (2022) Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma. Frontiers in Genetics 13.
Crossref
Crossref
Panagiota Gianni, Evangelia Matenoglou, Georgios Geropoulos, Nirav Agrawal, Harsha Adnani, Stefanos Zafeiropoulos, Santiago J. Miyara, Sara Guevara, James M. Mumford, Ernesto P. Molmenti & Dimitrios Giannis. (2022) The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data. Clinical Breast Cancer 22:1, pages 10-25.
Crossref
Crossref
Mengting Chen, Renske Linstra & Marcel A.T.M. van Vugt. (2022) Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188661.
Crossref
Crossref
Mengyu Tao & Xia Wu. (2021) The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang & Beihua Kong. (2020) MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Elahe Rahimian, Ali Amini, Fatemeh Alikarami, Seyed Mohammad Sadegh Pezeshki, Najmaldin Saki & Majid Safa. (2020) DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms. DNA Repair 96, pages 102951.
Crossref
Crossref
Rui Gou, Hui Dong & Bei Lin. (2020) Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sciences 261, pages 118434.
Crossref
Crossref
McKenzie K Grundy, Ronald J Buckanovich & Kara A Bernstein. (2020) Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer 2:3.
Crossref
Crossref
Can-Bin Fang, Hua-Tao Wu, Man-Li Zhang, Jing Liu & Guo-Jun Zhang. (2020) Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui & Liying Han. (2020) Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current Drug Targets 21:2, pages 167-178.
Crossref
Crossref
Natalia Soledad Paviolo, María Belén de la Vega, María Florencia Pansa, Iris Alejandra García, Nicolás Luis Calzetta, Gastón Soria & Vanesa Gottifredi. (2020) Persistent double strand break accumulation does not precede cell death in an Olaparib-sensitive BRCA-deficient colorectal cancer cell model. Genetics and Molecular Biology 43:1 suppl 1.
Crossref
Crossref
Doherty, Bryant, Valluru, Rennie & Sisley. (2019) Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma. Cancers 11:9, pages 1278.
Crossref
Crossref
Yucui Zhao & Siyu Chen. (2019) Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance. Current Drug Targets 20:9, pages 891-902.
Crossref
Crossref
Xuan Jiang, Xiaoying Li, Weihua Li, Huimin Bai & Zhenyu Zhang. (2019) PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of Cellular and Molecular Medicine 23:4, pages 2303-2313.
Crossref
Crossref
Erika Zernickel, Ali Sak, Assad Riaz, Diana Klein, Michael Groneberg & Martin Stuschke. (2019)
Targeting of BRM Sensitizes
BRG1
-Mutant Lung Cancer Cell Lines to Radiotherapy
. Molecular Cancer Therapeutics 18:3, pages 656-666.
Crossref
Crossref
Junhao Yan, Chao Zhou, Kuiyuan Guo, Qian Li & Zheng Wang. (2018) A novel seven‐lncRNA signature for prognosis prediction in hepatocellular carcinoma. Journal of Cellular Biochemistry 120:1, pages 213-223.
Crossref
Crossref
Andrea L. Bredemeyer, Bruce S. Edwards, Mark K. Haynes, Abigail J. Morales, Yinan Wang, Oleg Ursu, Anna Waller, Larry A. Sklar & Barry P. Sleckman. (2018) High-Throughput Screening Approach for Identifying Compounds That Inhibit Nonhomologous End Joining. SLAS Discovery 23:7, pages 624-633.
Crossref
Crossref
Marios Papadimitriou, Giannis Mountzios & Christos A. Papadimitriou. (2018) The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. Cancer Treatment Reviews 67, pages 34-44.
Crossref
Crossref
Carmen Chan, Bernard Law, Winnie So, Ka Chow & Mary Waye. (2017) Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. International Journal of Molecular Sciences 18:11, pages 2423.
Crossref
Crossref
Mary Glorieux, Rüveyda Dok & Sandra Nuyts. (2017) Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers. Oncotarget 8:46, pages 81662-81678.
Crossref
Crossref
Renier Vélez-Cruz & David Johnson. (2017) The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts. International Journal of Molecular Sciences 18:8, pages 1776.
Crossref
Crossref